C H Nielsen - JoVE Visualize

Showing results (21-30 of 52) with videos related to

Pageof 6

Sort By:

Immunology|March 20, 2002

CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytesC H Nielsen, H V Marquart, W M Prodinger, et al.

Anesthesiology|March 1, 1983

Influence of epinephrine as an adjuvant to epidural morphineP R Bromage, E M Camporesi, P A Durant, et al.

Undersea Biomedical Research|June 1, 1977

A method for measurement of the bubble formation threshold in biological liquidsL Bjorno, L O Kornum, P Krag, et al.

Clinical and Experimental Immunology|November 22, 2014

Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto's thyroiditisB Kristensen, L Hegedüs, H O Madsen, et al.

Scandinavian Journal of Rheumatology|October 2, 2018

Peptidylarginine deiminase-4 gene polymorphisms are associated with systemic lupus erythematosus and lupus nephritisL Massarenti, C Enevold, D Damgaard, et al.

Acta Anaesthesiologica Scandinavica|November 1, 1994

The redistribution of granulocytes following E. coli endotoxin induced sepsisP Toft, S T Lillevang, E Tønnesen, et al.

Journal of Endocrinological Investigation|December 21, 2010

Systemic adverse events following rituximab therapy in patients with Graves' diseaseD El Fassi, C H Nielsen, P Junker, et al.

Arthritis and Rheumatism|April 29, 1998

Diminished ability of erythrocytes from patients with systemic lupus erythematosus to limit opsonized immune complex deposition on leukocytes and activation of granulocytesC H Nielsen, J M Rasmussen, A Voss, et al.

Clinical and Experimental Immunology|June 1, 2006

Class switch recombination in selective IgA-deficient subjectsL Hummelshoj, L P Ryder, L K Nielsen, et al.

Alimentary Pharmacology & Therapeutics|May 9, 2013

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel diseaseC Steenholdt, Y Palarasah, K Bendtzen, et al.

Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:

Pageof 6

Immunology|March 20, 2002

CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytesC H Nielsen, H V Marquart, W M Prodinger, et al.

Anesthesiology|March 1, 1983

Influence of epinephrine as an adjuvant to epidural morphineP R Bromage, E M Camporesi, P A Durant, et al.

Undersea Biomedical Research|June 1, 1977

A method for measurement of the bubble formation threshold in biological liquidsL Bjorno, L O Kornum, P Krag, et al.

Clinical and Experimental Immunology|November 22, 2014

Altered balance between self-reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto's thyroiditisB Kristensen, L Hegedüs, H O Madsen, et al.

Scandinavian Journal of Rheumatology|October 2, 2018

Peptidylarginine deiminase-4 gene polymorphisms are associated with systemic lupus erythematosus and lupus nephritisL Massarenti, C Enevold, D Damgaard, et al.

Acta Anaesthesiologica Scandinavica|November 1, 1994

The redistribution of granulocytes following E. coli endotoxin induced sepsisP Toft, S T Lillevang, E Tønnesen, et al.

Journal of Endocrinological Investigation|December 21, 2010

Systemic adverse events following rituximab therapy in patients with Graves' diseaseD El Fassi, C H Nielsen, P Junker, et al.

Arthritis and Rheumatism|April 29, 1998

Diminished ability of erythrocytes from patients with systemic lupus erythematosus to limit opsonized immune complex deposition on leukocytes and activation of granulocytesC H Nielsen, J M Rasmussen, A Voss, et al.

Clinical and Experimental Immunology|June 1, 2006

Class switch recombination in selective IgA-deficient subjectsL Hummelshoj, L P Ryder, L K Nielsen, et al.

Alimentary Pharmacology & Therapeutics|May 9, 2013

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel diseaseC Steenholdt, Y Palarasah, K Bendtzen, et al.

Pageof 6